I am a corporate partner in the Life Sciences Group in our Paris office. My practice is focused on advising privately held emerging companies, with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, healthcare IT, digital health and wellness.
I represent life sciences and technology companies along the entire emerging company life-cycle, including pre-incorporation planning, formation and founder matters, seed, venture capital and growth equity financings, public offerings and mergers and acquisitions, joint venture and partnerships with pharmaceutical companies and other 'corporates'.
My goal is to create long-term relationships with my clients to assist them not only on their day-to-day business, but also on complex transactions, for their trade sale, their build up operations or for their IPO on Euronext or on other markets. I also represent French or foreign venture capital firms in connection with their investments in those life sciences companies.
I enjoy working with a genuine team of experts of the life sciences international team within Bird & Bird that can bring value to my clients, in particular in intellectual property, regulatory, IT, collaboration and licensing matters. I really feel that my corporate work for clients is enhanced by Bird & Bird's thorough knowledge of the life sciences industry in France and internationally.
For more than 10 years' I have been navigating the French life sciences ecosystem, meeting with serial entrepreneurs, researchers, scientists, engineers and financiers, which is a fascinating world facing huge challenges for the patients' health, including the revolution of artificial intelligence and the digitalisation of health. I feel, in all humility, that I am contributing to this noteworthy and exciting cause: helping fund health research.